JPRN-jRCT2080220962未知1 期
Clinical Evaluation of NK211 for Ovarian Cancer <Clinical pharmacological study>
ippon Kayaku Co., Ltd.0 个研究点开始时间: 2010年1月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •1)Histologic or cytologic diagnosis of ovarian cancer
- •2)Relapse-patients treated with standard chemotherapy
- •3)Patient whose prior therapy other than medication doesn't influence evaluation.
- •4)ECOG PS 0-2
排除标准
- 未提供
研究者
相似试验
未知
1 期
Clinical Evaluation of NK211 for Ovarian Cancer <Phase II study>Recurrent ovarian cancerJPRN-jRCT2080220963ippon Kayaku Co., Ltd.
进行中（未招募）
不适用
Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapyPlatinum refractory or resistant ovarian cancer, primary cancer of the peritoneum or fallopian tube (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or treatment free interval < 6 months after stop of platinum based chemotherapy)EUCTR2007-003089-16-DEAGO Research GmbH72
终止
2 期
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian CancerStage III Ovarian CancerStage IV Ovarian CancerNCT00003532Burzynski Research Institute7
进行中（未招募）
1 期
Sentinel lymph node assessment in ovarian cancer. Lymphatic mapping with two tracers and intraoperative lymphoscintigraphy.Sentinel lymph node in ovarian cancerMedDRA version: 20.0Level: LLTClassification code 10072873Term: Sentinel lymph node mappingSystem Organ Class: 100000004848EUCTR2020-005546-42-ESFundacio Clinic per a la Recerca Biomedica62
已完成
不适用
orth Thames CA125 study in advanced ovarian cancerOvarian cancerCancerISRCTN75843298K Co-ordinating Committee for Cancer Research (UKCCCR)237